Beatrice Hull, MD
Endocrinology, Diabetes & Metabolism · Charleston, SCNPI 1396832382
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $177,754 of the $214,216 with a category attached, or 83.0%. Novo Nordisk accounts for 73.9% of it on its own, with 53 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 803 payments — averaging $266.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$158K
- Lilly USA, LLC$25K
- Boehringer Ingelheim$19K
- AbbVie$3K
- Amgen$836
- Abbott$681
- plus $7K from 48 others
Across 59 payments — averaging $13,120 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$724K
- Radius Health, Inc.$32K
- AstraZeneca$18K
What the payments were for
- Speaking & faculty fees$177,75483%
- Travel & lodging$20,1619%
- Food & beverage$16,2408%
- Education$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$72,100
- RYBELSUS$71,116
- JARDIANCE$42,209
- Synthroid$2,143
- CeQur Simplicity$362
- TEPEZZA$124
- Pogo Automatic Blood Glucose Monitoring System$120
- Tymlos$117
- Tresiba$115
- TOUJEO$102
How this compares
$214,216 in reported general payments places this provider in the 90th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 269 | $377,643 |
| JardianceEmpagliflozin | 123 | $137,451 |
| Somatuline DepotLanreotide Acetate | 12 | $114,973 |
| ForteoTeriparatide | 26 | $110,154 |
| MounjaroTirzepatide | 41 | $58,108 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 36 | $35,473 |
| TymlosAbaloparatide | 12 | $30,388 |
| FarxigaDapagliflozin Propanediol | 30 | $24,034 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $21,552 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $20,329 |
| SynthroidLevothyroxine Sodium | 221 | $19,019 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $17,413 |
| RybelsusSemaglutide | 13 | $14,295 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $14,076 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $13,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $158,245 | $400,476302 claims |
| Lilly USA, LLCForteo, Mounjaro, Humalog, Insulin Lispro | $25,337 | $177,157115 claims |
| Boehringer IngelheimJardiance | $19,387 | $137,451123 claims |
| Radius Health, Inc.Tymlos | $477 | $30,38812 claims |
| AstraZenecaFarxiga | $326 | $24,03430 claims |
| AbbVieSynthroid | $2,971 | $19,019221 claims |
| IBSA Pharma Inc.Tirosint | $625 | $5,59318 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $173 | $1,930211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Charleston
- Louis HaenelCharleston$377K
- Jaimin PatelCharleston$37K
- Jyotika FernandesCharleston$12K
- Kathie HermayerCharleston$4K
- Eliana MilazzoCharleston$2K
- Gauri DhirMyrtle Beach$417K
- Cory WhiteGreenville$413K
- Vonda CalcuttWalterboro$368K
- Ray VaughtersAiken$321K
- Donald EagertonMyrtle Beach$284K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.